Pfizer Delivers A Strong Q2 2025 and Raises Full Year EPS Guidance

Pfizer delivered strong performance in the second quarter of 2025, reflecting progress in improving R&D productivity, higher margins from disciplined cost management, and commercial success. Read more

We Invest in Changing Lives

Welcome to our shareholder community. Here you will find updates on our innovation pipeline progress, performance results, and corporate milestones. You’ll also have the opportunity to hear from our management team. Sign up now for Pfizer Investor Insights to receive information about the company and your investment.

Investors, Submit Your Question to Pfizer

We want to hear from you to help ensure that we are providing content that is informative and relevant.

Submit a question here about Pfizer’s R&D pipeline, Pfizer’s capital allocation objectives, or Pfizer’s roadmap for the future.

In the coming weeks and months, we’ll compile answers to common questions, giving you a way to hear from management on topics of interest to you.

"We believe we have a clear strategy, scientific leadership and strong capabilities that position us to create sustained, long-term value for shareholders and positive impact for the patients and others we're privileged to serve."

Albert Bourla

Chairman and Chief Executive Officer

Current Stock Price

$25.72 0.469%

Day High

$25.72

52 Wk High

$31.54

Day Low

$31.54

52 Wk Low

$31.54

03/14/2025 16:00:00

Stories & News

Take a closer look at how our leadership in biopharma is driving innovation, changing patients’ lives and delivering strong returns for shareholders.

Explore the latest

Our R&D Engine: Proven Success in Bringing Revolutionary Drugs to Market

Pioneering the Future of Healthcare: Pfizer’s AI Advantage

In Conversation with Andrew Baum: Exploring Pfizer's Long-Term Vision

Resources

Essential Facts and Figures for Shareholders

Get access to our latest financial information, strategy and presentations.

Explore

Join Pfizer Investor Insights

Sign up to receive important updates about Pfizer, how we’re innovating for patients and delivering value for shareholders. Email updates will also provide exciting opportunities for individual shareholders to hear from our leadership and experts.

Sign up to hear directly from our leadership and experts and to read about how we’re innovating for our patients while delivering value for our shareholders.

I would like to receive information, updates, and hear from leadership regarding Pfizer Investor Insights and other investor relations initiatives in accordance with Pfizer’s Privacy Policy

Forward-looking statements included herein are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website.

Copyright © 2002 – 2025 Pfizer Investor Insights All rights reserved. This information—including product information—is intended only for residents of the United States. The products discussed herein may have different labeling in different countries. This website contains certain information about Pfizer, but may not contain all information that is material to Pfizer.